Get the Stockscreener App
1.15
2.54%
-0.03
After Hours:
1.16
0.01
+0.87%
Quince Therapeutics Inc stock is traded at $1.15, with a volume of 581.72K.
It is down -2.54% in the last 24 hours and down -6.50% over the past month.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
See More
Previous Close:
$1.18
Open:
$1.18
24h Volume:
581.72K
Relative Volume:
0.08
Market Cap:
$18.75M
Revenue:
-
Net Income/Loss:
$-83.98M
P/E Ratio:
-0.0861
EPS:
-13.3519
Net Cash Flow:
$-41.78M
1W Performance:
-10.16%
1M Performance:
-6.50%
6M Performance:
-93.15%
1Y Performance:
-86.29%
1-Day Range:
$1.14
$1.18
1-Week Range:
$1.14
$1.27
52-Week Range:
$0.80
$45.50
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.15 | 19.23M | 0 | -83.98M | -41.78M | -13.35 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
QNCX Should I Buy - Intellectia AI
Nantahala Capital (QNCX) reports 4.53M shares, 7.52% stake disclosed - Stock Titan
Quince Therapeutics (QNCX) price target increased by 100.00% to 81.60 - MSN
Quince Therapeutics stock (US74833Q1004): Analysts see 345% upside potential - AD HOC NEWS
Quince Therapeutics (QNCX) price target increased by 900.00% to 40.80 - MSN
QNCX Stock Chart | QUINCE THERAPEUTICS INC (NASDAQ:QNCX) - ChartMill
TradingKey - TradingKey
Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN
QUE THERAPEUTICS ($QNCX) Releases Q1 2026 Earnings - Moomoo
Quince Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Trial setback and cash strain shape Quince (NASDAQ: QNCX) Q1 update - Stock Titan
Quince Therapeutics Inc expected to post a loss of $2.56 a shareEarnings Preview - TradingView
MSN Money - MSN
Quince Therapeutics Regains Nasdaq Bid Compliance Amid Valuation Risk - The Globe and Mail
Quince Therapeutics (QNCX) restores bid compliance but still below $50M MVLS - Stock Titan
Quince regains Nasdaq bid-price compliance but MVLS deficiency remains - TradingView
Large reverse split, director election on deck at Quince Therapeutics (QNCX) meeting - Stock Titan
SEC Form DEFA14A filed by Quince Therapeutics Inc. - Quantisnow
Quince Therapeutics settles $16.4M debt with $5.5M payment - MSN
Quince Therapeutics (QNCX) price target decreased by 21.74% to 6.12 - MSN
Why did QNCX stock plummet over 90% today? - MSN
Quince Therapeutics Appoints June Bray to Board - The Globe and Mail
Quince Therapeutics appoints June Bray to board of directors By Investing.com - Investing.com Canada
Quince Therapeutics appoints June Bray to board of directors - Investing.com
[8-K] Quince Therapeutics, Inc. Reports Material Event - Stock Titan
Quince Therapeutics, Inc. Appoints June Bray as Class I Director and to Nominating & Governance Committee, Audit Committee, and Compensation Committee, Effective April 22, 2026 - marketscreener.com
QNCX Stock Price, Quote & Chart | QUINCE THERAPEUTICS INC (NASDAQ:QNCX) - ChartMill
Quince Therapeutics (QNCX) Stock: Worth Entering? (-6.93%) 2026-04-20Top Breakouts - Xã Vĩnh Công
QNCX Sees Increased Price Target Amidst Maintained Buy Rating | - GuruFocus
Quince Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):